Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

799 results about "Selective inhibition" patented technology

Wiktionary(0.00 / 0 votes)Rate this definition: selective serotonin reuptake inhibitor(Noun) Any of a class of drugs, such as fluoxetine or sertraline, that inhibit the uptake of serotonin in the central nervous system and are often used to treat certain mental illnesses, such as depression.

Fused tetracyclic compounds and use thereof

The invention relates to compounds of formula (I), a stereoisomer thereof, a pharmaceutically acceptable salt thereof, a pharmaceutically acceptable salt of the stereoisomer thereof, a prodrug thereof, a deuterated molecule thereof or a PROTAC molecule thereof that selectively inhibit the activity of K-Ras G12D protein, compositions comprising the same, the methods of using the same and related intermediates.
Owner:JACOBIO PHARMACEUTICALS CO LTD

Fluoroquinoxalinone derivatives that selectively inhibit PARP1

The present invention discloses a series of fluorine-substituted heterocyclic compounds, specifically, compounds represented by formula (XII) and pharmaceutically acceptable salts thereof. 【Chemical 1】 JPEG2025516367000403.jpg44170
Owner:サイブランチ セラピューティクス カンパニー リミテッド

Methods of treating a ras protein-related disease or disorder

Disclosed are RAS(ON) multi-selective inhibitor compositions and methods of treating RAS protein-related diseases or disorders using an intermittent dosing regimen. RAS(ON) multi-selective inhibitors having tight binding to cyclophilin A (CypA) result in high exposure levels, prolonged tissue retention, and / or slow clearance rates, thereby increasing the risk of inhibition of wild-type RAS in normal tissues. Accordingly, provided herein are methods for the safe and effective dosing of low KD1 RAS(ON) multi-selective inhibitors using an intermittent dosing regimen. Also provided are methods of selecting or identifying such RAS(ON) multi-selective inhibitors suitable for intermittent administration.
Owner:REVOLUTION MEDICINES INC

DHCR24 inhibitory compounds

The present disclosure relates to compounds suitable for the inhibition of [Delta] 24-dehydrocholesterol reductase (DHCR24), in particular the selective inhibition of DHCR24. These compounds are useful as therapeutic agents, in particular as agents for the treatment and / or prophylaxis of DHCR24 mediated conditions, such as non-alcoholic steatohepatitis (NASH), atherosclerotic cardiovascular disease (asCVD) or multiple sclerosis (MS).
Owner:ACADEMISCH ZIEKENHUIS LEIDEN (H O D N LUMC)

N, Napos; preparation method of-bis (2-bromo / chloroethyl) diamino phosphonic acid (1-methyl-4-nitro-1H-imidazole-2-cyanogen) methyl ester

The invention belongs to the technical field of chemical synthesis, and particularly relates to a preparation method of N, N '-bis (2-bromine / chloroethyl) diamino phosphonic acid (1-methyl-4-nitro-1H-imidazole-2-cyanogen) methyl ester, 4-methylimidazole is used as a raw material, and (1-methyl-4-nitro-1H-imidazole-2-cyanogen) methanol is synthesized through nitration, methyl substitution, bromine substitution, bromomethyl substitution, hydrolysis and substitution; the preparation method comprises the following steps: reacting phosphorus oxychloride with ethyl amine salt to synthesize N, N '-bis (2-bromoethyl) diamino phosphonic acid and N, N'-bis (2-chloroethyl) diamino phosphonic acid, and finally condensing to obtain N, N '-bis (2-bromoethyl) diamino phosphonic acid (1-methyl-4-nitro-1H-imidazole-2-cyanogen) methyl ester and N, N'-bis (2-chloroethyl) diamino phosphonic acid (1-methyl-4-nitro-1H-imidazole-2-cyanogen) methyl ester. The compound can selectively inhibit ovarian cancer cell proliferation under a hypoxia condition.
Owner:CHANGZHOU UNIV

EGFR (Epidermal Growth Factor Receptor) mutation-targeted dimethyl phosphine oxide substituted aniline pyrimidine derivative, preparation method and application thereof and medicine prepared from EGFR mutation-targeted dimethyl phosphine oxide substituted aniline pyrimidine derivative

The invention belongs to the technical field of medicines, and relates to a dimethyl phosphine oxide substituted aniline pyrimidine derivative targeting EGFR mutation, a preparation method and application thereof, and a medicine prepared from the dimethyl phosphine oxide substituted aniline pyrimidine derivative. The invention provides a compound as shown in a formula I. The compounds have outstanding inhibitory activity (at a nanomole level) and selectivity on EGFRT790M / C797S / L858R kinase and EGFRL858R / T790M kinase, have an obvious inhibitory effect on a non-small cell lung cancer cell line, particularly have outstanding selectivity on EGFR mutant cells H1975, and have an obvious inhibitory effect. The compound disclosed by the invention has a remarkable tumor inhibition effect in a nude mouse heterophylloma model and is relatively low in in-vivo toxicity. Therefore, the compound provided by the invention can be used as an epidermal growth factor receptor tyrosine kinase inhibitor to be applied to preparation of anti-lung cancer drugs, and has a good application prospect. And the formula I of the # imgabs0 # is shown in the specification.
Owner:WEST CHINA HOSPITAL SICHUAN UNIV

FGFR2 / 3 selective inhibitor, pharmaceutical composition and use thereof

Provided are a compound represented by formula (I) and a racemate, a stereoisomer, a tautomer, an isotope label, an oxynitride, a solvate, a polymorph, a metabolite, an ester, a prodrug, or a pharmaceutically acceptable salt thereof. The compound has a good FGFR2 / 3 inhibitory effect, and can be used for treating or preventing FGFR2 / 3-mediated disorders and diseases, and preparing drugs for treating or preventing such disorders and diseases.
Owner:CHANGCHUN GENESCIENCE PHARM CO LTD

Application of honeysuckle polysaccharide in preparation of medicine for treating thyroid cancer

The invention relates to the technical field of drugs for treating thyroid cancer, in particular to application of honeysuckle polysaccharide in preparation of drugs for treating thyroid cancer. According to the technical scheme, on the basis of separating and purifying the honeysuckle polysaccharide with relatively good uniformity, the honeysuckle polysaccharide is found to have no toxic effect on normal thyroid follicular cells, but selectively inhibits proliferation of recurrent metastatic papillary thyroid carcinoma cells, and has an inhibiting effect on transplanted tumors of nude mice inoculated with a recurrent metastatic papillary thyroid carcinoma cell line. According to the scheme, the honeysuckle flower polysaccharide is good in homogeneity, the molecular weight is 23 + / -4 kDa, the honeysuckle flower polysaccharide is mainly composed of five monosaccharides, and alpha-(1-> 4)-D-GalpA is mainly connected to form a main chain. The polysaccharide has no toxic effect on normal thyroid cells while effectively inhibiting the cell viability of IHH-4. According to the technical scheme, the technical problem that drugs for treating recurrent metastatic papillary thyroid carcinoma with small side effects and high specificity are lacked in the prior art can be solved, and the drug has an ideal application prospect.
Owner:THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV

Oxadiazole HDAC6 inhibitors and uses thereof

Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and / or compositions described herein.
Owner:EIKONIZO THERAPEUTICS INC

Pyrazolo[3,4-d]pyrimidinone compounds for the treatment of chronic heart failure

This application relates to a series of novel compounds that are selective inhibitors of phosphodiesterase type 9 ("PDE9") for the treatment of chronic heart failure. More particularly, the application relates to pyrazolo[3,4-d]pyrimidinone compounds for use in the treatment and prevention of chronic heart failure.
Owner:CARDURION PHARMA INC

Compound as voltage-gated sodium channel inhibitor and use thereof

PCT designated stageWO2025218764A1Organic active ingredientsOrganic chemistrySodium Channel InhibitorsVisceral pain
The present invention relates to a voltage-gated sodium channel Nav1.8 selective inhibitor and the use thereof in the preparation of a related drug. The drug is used for treating diseases responsive to the inhibition of voltage-gated sodium channel NaV1.8, such as chronic pain, enterodynia, neuropathic pain, musculoskeletal pain, acute pain, inflammatory pain, cancer pain, idiopathic pain, post-operative pain, visceral pain, multiple sclerosis, Charcot-Marie-Tooth syndrome, incontinence, pathological cough or arrhythmia. Specifically, the present invention relates to a compound as shown in formula (X), and an isomer, nitrogen oxide, hydrate, solvate, metabolite, pharmaceutically acceptable salt or prodrug thereof.
Owner:GUANGZHOU UNIRISE PHARM CO LTD +3

Polo-like kinase 1 inhibitors

The present invention relates to inhibitors of polo-like kinase 1 ("PLK1"). In particular, the present invention relates to compounds that selectively inhibit the activity of PLK1, pharmaceutical compositions comprising a therapeutically effective amount of the compounds, and methods of use therefor, such as methods for treating PLK1 -mediated diseases and disorders, such as cancer.
Owner:RESERO THERAPEUTICS LLC

Stable pharmaceutical compositions of a CYP11a1 inhibitor

PCT designated stage expiredWO2025017072A1Organic active ingredientsPill deliveryDiseaseTherapeutic Hormone
The present invention relates to a pharmaceutical composition for oral administration, for example in the form of a tablet or a powder suitable to be filled into a capsule shell, comprising 2-(isoindolin-2-ylmethyl)-5-((1-(methylsulfonyl)- piperidin-4-yl)methoxy)-4H-pyran-4-one (I) or a pharmaceutically acceptable salt thereof as an active ingredient. Compound (I) or a pharmaceutically acceptable salt thereof is a selective inhibitor of CYP11A1 enzyme and is useful in the treatment of hormonally regulated diseases such as cancer including prostate cancer and breast cancer.
Owner:ORION CORP(FI)

Isoform-selective TGFB1 inhibitors and use thereof

Disclosed herein are monoclonal antibodies and antigen-binding fragments thereof capable of selectively inhibiting TGFβ1 with high potency. Related compositions, methods and therapeutic use are also disclosed.
Owner:SCHOLAR ROCK INC

Selective KRAS G12C inhibitors and uses thereof

The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof and methods of making and using the compounds and salts. Certain compounds described herein are surprisingly potent and more effective in inhibiting cancer cell proliferation driven at least in part by a KRAS protein having a G12C mutation. Certain compounds are particularly useful in methods for the treatment of cancer mediated, in whole or in part, by KRAS G12C mutation, and the efficacy of the compounds offers certain advantages to achieve therapeutic benefits.
Owner:1200 PHARM CO LTD +1

Substituted thiazolidinedione compound and application thereof

The invention relates to the field of medicinal chemistry, in particular to a substituted thiazolidinedione compound and application thereof. Pharmacological test results show that when the concentration of the synthesized compound is 10 [mu] M, the inhibition rate of the synthesized compound on SphK1 is weaker than that of a positive control drug PF-543, but the inhibition rate of most of the synthesized compounds on SphK2 is superior to that of a positive control drug K145, and the synthesized compound shows an ideal selective inhibition effect on SphK2.
Owner:SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI

Combination therapy for treating cancer

The present provides a method of treating ovarian cancer, breast cancer, gastrointestinal cancer, lung cancer, cancer of the brain or prostate cancer in a subject in need thereof, comprising administering to the subject a first amount of a selective PARP1 inhibitor or a pharmaceutically acceptable salt thereof, and a second amount of an ATR inhibitor or a pharmaceutically acceptable salt thereof. Also disclosed are compositions and kits comprising a PARP inhibitor and ATR inhibitor.
Owner:ASTRAZENECA AB

Click type covalent drug and regioselective delivery system and application thereof

The invention discloses a click type covalent drug as well as a regioselective delivery system and application thereof. The click-type covalent drug delivery system comprises a click-type covalent drug and a tumor region selective delivery system, and the click-type covalent drug is composed of aza-cyclic alkyne (DBCO), a small molecule drug and a linker and has a structure as shown in a formula 1. Optionally, the small molecule drugs are membrane protein inhibitors, immunomodulators, chemotherapeutic drugs and the like. The click-type covalent drug and the azide-labeled target cell are subjected to a click reaction to form a covalent bond to be combined on a cell membrane, so that the local drug concentration is improved, the drug retention time is prolonged, and the selective inhibition on the target cell is enhanced; the regioselective delivery system is formed by co-assembling an amphiphilic block polymer and a click type covalent drug, and is used for regioselective delivery. By means of the click type covalent drug, covalent binding of azide-labeled tumor cells is achieved, normal cells which are not labeled by azide are not affected, and toxic and side effects on normal tissue are reduced. # imgabs0 #
Owner:EAST CHINA NORMAL UNIV +1

Nonmuscle myosin ii inhibitors

The invention can provide compounds, analogs of blebbistatin, effective and selective inhibitors of nonmuscle myosin II relative to cardiac myosin II. Compounds can be used in the method of treating a disease, disorder, or medical condition in a patient, comprising modulating myosin II ATPase, such as treatment of substance abuse relapse disorder, or of renal disease, cancer and metastasis, benign prostate hyperplasia, hemostasis or thrombosis, nerve injury including retinal damage, lung fibrosis, liver fibrosis, arthrofibrosis, wound healing, spinal cord injury, periodontitis, glaucoma and immune-related diseases including multiple sclerosis; or wherein the disease, disorder, or medical condition comprises addiction including abuse of or addiction to anything classified as a Substance-Related or Addictive Disorder in the Diagnostic and Statistical Manual of Mental Disorders (DSM), such as, but not limited to, cocaine, opioids, amphetamines, ethanol, cannabis / marijuana, nicotine, and activities including gambling.Compounds are of general formulawith substituents as defined herein.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Fluorite flotation composite inhibitor and preparation method and application thereof

The invention provides a fluorite flotation composite inhibitor and a preparation method and application thereof.The composite inhibitor can be used for flotation of phosphorus-containing high-calcium low-grade fluorite mine and comprises, by mass, 1-5 parts of sodium hexametaphosphate, 8-40 parts of sodium humate, 2.8-14 parts of tannin extract, 5-40 parts of water glass and 0.2-1 part of sodium acrylate. The preparation method comprises the following steps: S1, dissolving sodium hexametaphosphate, water glass and sodium acrylate in water to obtain a mixed solution; and S2, adding the tannin extract and the sodium humate into the mixed solution, and uniformly mixing the tannin extract and the sodium humate. The fluorite flotation composite inhibitor is high in selective inhibition performance, small in influence on floatability of fluorite while inhibiting calcite and apatite, better in selective inhibition effect compared with a single traditional inhibitor such as water glass and the like, capable of achieving efficient separation of calcite, apatite and other calcium-containing gangue minerals and fluorite and capable of achieving efficient flotation of fluorite. And high-quality and high-recovery-rate fluorite concentrate is obtained, and the comprehensive benefits of the flotation process are greatly improved.
Owner:CHANGSHA RES INST OF MINING & METALLURGY CO LTD

Preparation and application of novel MAO-B inhibitor containing tetrahydronaphthalene-1-amine structure

The invention provides preparation and application of a novel MAO-B inhibitor containing a tetrahydronaphthalene-1-amine structure, and belongs to the field of medicine. The derivative is a compound as shown in a formula I, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof. The compound disclosed by the invention can be used for inhibiting MAO (monoamine oxidase), and particularly can be used for selectively inhibiting MAO-B; the compound can be used for treating Parkinson's disease, Alzheimer's disease, emotional disorder and other diseases, and has a good application prospect.
Owner:CHONGQING MEDICAL UNIVERSITY

Application of quaternary ammonium cation modified cellulose as talc inhibitor

The invention discloses application of quaternary ammonium cation modified cellulose as a talc inhibitor, and belongs to the technical field of mineral separation. The quaternary ammonium cation modified cellulose has the following molecular structural formula: # imgabs0 #, R1, R2 and R3 are independently selected from hydrogen or quaternary ammonium salt groups, and at least one of R1, R2 and R3 is a quaternary ammonium salt group; and m / (m + n) is equal to 0.18-0.90. The talc flotation inhibitor has a good selective inhibition effect on talc flotation, and is particularly suitable for efficient flotation separation of metal sulfide ores (such as molybdenite, galena and sphalerite) and talc.
Owner:CENT SOUTH UNIV

Substituted pyrimidine-fused ring inhibitor, method for preparing same, and use thereof

The present invention relates to a substituted pyrimidine-fused ring inhibitor, a method for preparing same, and use thereof. Specifically, the compound of the present invention has a structure represented by formula (I). Further disclosed are a method for preparing the compound, and use of the compound as a KRAS mutation inhibitor. The compound has a good selective inhibition effect on KRAS mutation and has better pharmacodynamic and pharmacokinetic performance and lower toxic and side effects.
Owner:SUZHOU ZELGEN BIOPHARML +1

HDAC6 inhibitors and uses thereof

Provided herein are compounds that selectively inhibit HDAC6, a protein whose activity is associated with a variety of diseases (e.g., cancer, neurological disorders). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating HDAC6-related diseases and disorders (e.g., Alzheimer's disease, cancer) with the compounds in a subject, by administering the compounds and / or compositions described herein.
Owner:EIKONIZO THERAPEUTICS INC